SEC filing summary
Identity note: The request identifies TALPHERA, INC., but the supplied Form 10-Q is for AcelRx Pharmaceuticals, Inc. This summary reflects the filing provided, for the quarter ended September 30, 2014, filed November 10, 2014. Financial amounts are in U.S. dollars; statements present amounts in thousands unless noted.
Business context and reporting period
AcelRx is a specialty pharmaceutical company developing therapies for acute and breakthrough pain. It had no product sales. Its lead candidate, Zalviso, is a sufentanil tablet-and-device system intended for hospital acute pain; ARX-04 is an additional development program. Results cover the three and nine months ended September 30, 2014, compared with the same 2013 periods.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $4.825 million | $0.548 million | $4.991 million | $1.895 million |
| Operating expenses | $9.894 million | $8.858 million | $30.861 million | $28.545 million |
| Operating loss | $5.069 million | $8.310 million | $25.870 million | $26.650 million |
| Net income (loss) | $0.671 million | $(10.986) million | $(19.535) million | $(41.195) million |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $(25.535) million | $(25.935) million |
- Q3 revenue was primarily collaboration revenue from Grünenthal: $4.6 million of its $5.0 million MAA-submission milestone was recognized, plus $264,000 for development work. No USAMRMC research-grant revenue was recognized in 2014.
- Q3 reported net income reflected a $6.4 million gain from revaluing PIPE warrant liabilities; diluted loss per share was $(0.13), versus basic earnings per share of $0.02. Nine-month basic and diluted loss per share were $(0.45) and $(0.63), respectively. These results do not indicate recurring product profitability.
- R&D expense declined 20% in Q3 and 22% for the nine-month period, mainly due to lower Zalviso trial and filing costs. G&A expense rose 101% and 107%, respectively, reflecting market research, staffing, consulting and professional services. Interest expense increased with higher Hercules borrowing.
- At September 30, cash and cash equivalents were $70.241 million and short-term investments were $15.329 million, totaling $85.570 million, down from $103.663 million at December 31, 2013. Current assets were $86.641 million and current liabilities $10.367 million.
- Debt principal outstanding was $25.0 million; reported long-term debt carrying value was $24.869 million, including current and noncurrent portions. Total liabilities were $37.365 million. The company had no commercial product revenue and an accumulated deficit of $164.988 million.
- Nine-month investing cash use was $5.011 million, including $4.756 million for property and equipment; financing provided $12.386 million, mainly from a $10.0 million Hercules draw. Cash decreased $18.160 million over the period.
Material changes versus prior comparable periods
- Q3 revenue rose from $548,000 to $4.825 million, while nine-month revenue rose from $1.895 million to $4.991 million, primarily reflecting the Grünenthal collaboration rather than product sales.
- Q3 net results swung to reported income from loss, driven chiefly by warrant-liability revaluation gains. Nine-month net loss also narrowed substantially, in part because the prior-year period included a large warrant revaluation expense.
- R&D spending decreased, but G&A and interest expense increased. Operating cash use remained broadly similar to 2013, while 2014 financing was lower because the comparable 2013 period included a $47.944 million public equity offering.
- Cash and investments fell by about $18.1 million from year-end 2013. Debt rose after the company drew the second $10 million tranche in June 2014.
Outlook, risks and unusual items
- Zalviso: The FDA issued a Complete Response Letter on July 25, 2014, requesting additional device-related information, including testing to reduce optical-system errors, revised instructions addressing inadvertent dosing, and shelf-life support. After meeting with FDA, the company planned to submit bench-testing and Human Factors Study protocols for review and targeted NDA resubmission in Q1 2015. Timing and approval depended on FDA feedback and study results; the planned resubmission was expected to receive a six-month Class 2 review.
- ARX-04: The company planned Phase 3 trials in 2015, but was negotiating a Department of Defense development-funding contract and could defer trial initiation pending completion. It proposed using about 300 Zalviso-program patients toward the 500-patient safety database, subject to FDA agreement.
- Liquidity: Management expected existing resources to fund operations through at least 2015, based on assumptions including FDA approval of Zalviso. The company warned that resources might be inadequate if approval or commercialization were delayed, and that additional financing might be required. A possible third Hercules tranche of up to $15 million was conditional on FDA approval and available through August 1, 2015; the loan was secured by substantially all assets other than intellectual property. Interest-only payments were scheduled through April 2015, with potential extensions tied to approval.
- Grünenthal: The European/Australian collaboration included a $30 million upfront payment received in 2013, a $5 million MAA-submission milestone received in 2014, a possible $15 million MAA-approval milestone, and approximately $200 million of further potential development, regulatory and sales milestones. These amounts are contingent; future royalties and fees depend on sales and approvals.
- Legal and governance: A securities class action filed October 1, 2014 alleged misleading statements concerning Zalviso instructions and shelf-life data. The company said it intended to defend itself; damages sought were unspecified. The filing also reports that on November 5 the board began a search to replace CEO Richard King, who would remain during the transition.
- Other material risks include continued operating losses, regulatory and study delays, dependence on third-party manufacturing and limited supply capacity, controlled-substance quotas, commercialization and reimbursement uncertainty, and potential dilution or financing constraints. Management reported disclosure controls effective at a reasonable-assurance level and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the issuer and filing match the intended company: the supplied document is AcelRx Pharmaceuticals, Inc., not Talphera, Inc.
- Track FDA review of the bench-testing and Human Factors protocols, completion and results of the studies, NDA resubmission timing, and any further FDA requirements.
- Assess cash runway against operating cash use, the conditional availability of the third Hercules tranche, debt service and potential financing needs.
- Separate recurring operating performance from noncash warrant revaluation gains and confirm collaboration revenue recognition and milestone contingencies.
- Monitor the Grünenthal MAA review and milestone potential, ARX-04 DoD contract negotiations and Phase 3 timing, and the securities litigation and CEO transition.